Skip to content
Search

Latest Stories

AstraZeneca resumes UK vaccine trials after pause due to patient illness

PHARMA giant AstraZeneca has resumed British clinical trials of its Covid-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs.

The late-stage trials of the experimental vaccine, developed with researchers from the University of Oxford, were suspended this week after an illness in a study subject in Britain, casting doubts on an early rollout.


"On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators," AstraZeneca said on Saturday (12).

It added that safety reviewers had recommended to Britain's Medicines Health Regulatory Authority (MHRA) that it was safe to resume the British trials.

The patient involved in the study had been reportedly suffering from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis.

AstraZeneca, based in Cambridge, said it could not disclose further medical information.

"The Company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic," AstraZeneca said.

It declined to elaborate further on when other global trials were expected to restart.

The Serum Institute of India said it would restart its trials once it had permission from the Drugs Controller General of India.

Governments around the world are desperate for a vaccine to help end the pandemic, which has caused more than 900,000 deaths and global economic turmoil. The World Health Organization (WHO) had flagged AstraZeneca's as the most promising.

The vaccine is in late-stage clinical trials in the United States, Britain, Brazil and South Africa and additional trials are planned in Japan and Russia.

'WAKE-UP CALL'

The pause of the trials came after reports that the United States was aiming for fast-track authorization or approval of a vaccine before November's presidential election.

Leading U.S. and European vaccine developers have pledged to uphold scientific safety and efficacy standards for their experimental vaccines and not bow to political pressures to rush the process.

AstraZeneca has already agreed to supply close to three billion doses to governments across the globe - more than any other vaccine project.

The WHO's chief scientist said the pause in the trials should serve as a "wake-up" call that there would be ups and downs in the development of a vaccine.

"Inevitably with such a large trial there will be times when safety issues arise," said Peter Openshaw, professor of experimental medicine at Imperial College London.

"We must all hope that there are no future events and that the vaccine proves both safe and effective."

More For You

​Dilemmas of dating in a digital world

We are living faster than ever before

AMG

​Dilemmas of dating in a digital world

Shiveena Haque

Finding romance today feels like trying to align stars in a night sky that refuses to stay still

When was the last time you stumbled into a conversation that made your heart skip? Or exchanged a sweet beginning to a love story - organically, without the buffer of screens, swipes, or curated profiles? In 2025, those moments feel rarer, swallowed up by the quickening pace of life.

Keep ReadingShow less
sugary drinks and ice cream

Researchers from the UK and US analysed data from American households between 2004 and 2019

iStock

Global warming may drive higher consumption of sugary drinks and ice cream, study warns

Highlights:

  • Hotter days linked to greater intake of sugary drinks and frozen desserts
  • Lower-income households most affected, research finds
  • Climate change could worsen health risks linked to sugar consumption
  • Study based on 15 years of US household food purchasing data

Sugary consumption rising with heat

People are more likely to consume sugary drinks and ice cream on warmer days, particularly in lower-income households, according to new research. The study warns that climate change could intensify this trend, adding to health risks as global temperatures continue to rise.

Sugar consumption is a major contributor to obesity, diabetes, and cardiovascular disease, and has surged worldwide in recent decades. The findings, published in Nature Climate Change, suggest that rising heat could be nudging more people towards high-sugar products such as soda, juice and ice cream.

Keep ReadingShow less
Camellia Panjabi's cookbook elevates
vegetables from sides to stars

Camellia Panjabi (Photo: Ursula Sierek)

Camellia Panjabi's cookbook elevates vegetables from sides to stars

RESTAURATEUR and writer Camellia Panjabi puts the spotlight on vegetables in her new book, as she said they were never given the status of a “hero” in the way fish, chicken or prawns are.

Panjabi’s Vegetables: The Indian Way features more than 120 recipes, with notes on nutrition, Ayurvedic insights and cooking methods that support digestion.

Keep ReadingShow less
Spotting the signs of dementia

Priya Mulji with her father

Spotting the signs of dementia

How noticing the changes in my father taught me the importance of early action, patience, and love

I don’t understand people who don’t talk or see their parents often. Unless they have done something to ruin your lives or you had a traumatic childhood, there is no reason you shouldn’t be checking in with them at least every few days if you don’t live with them.

Keep ReadingShow less
HH Guruji performed the Dhwaja Ritual at Ambaji Temple

HH Guruji performed the Dhwaja Ritual at Ambaji Temple

Mahesh Liloriya

The holy town of Ambaji witnessed a spiritually significant day on Sunday as His Holiness Siri Rajrajeshwar Guruji, head of the International Siddhashram Shakti Centre, London, performed the Dhwaja ritual at the historic Ambaji Temple in Gujarat, one of the most revered Shakti Peeths of India.

Keep ReadingShow less